Alzheimer’s Benefits May Continue After Donanemab Treatment Ends, Data Suggest
(MedPage Today) — New data suggested that donanemab (Kisunla) sustained long-term benefits after a limited dosing period in a subgroup of people with early symptomatic Alzheimer’s disease.
Early Alzheimer’s patients who completed their course…
Share this Post
More Posts
What Do Pediatricians Really Think of Minecraft?
(MedPage Today) — Welcome to Culture Clinic, MedPage Today’s collaboration with Northwell Health to offer a healthcare professional’s take on
Novel Alzheimer’s Drug Targeting Tau Shows Promise in Mid-Stage Trial
(MedPage Today) — The tau-targeting agent diranersen did not meet the primary endpoint of the phase II CELIA trial, but
Protected: Untold KFF History Volume Three: The Global Media AIDS Initiative
There is no excerpt because this is a protected post.
Subscribe to our Newsletter
Executive Orders
Latest Posts
Mental & Behavioral Health
GLP-1s and Blinding Condition; Cyclosporiasis Source Found? Tylenol-Autism Lawsuits
Environmental & Climate Health Sciences
Eating chili peppers may raise the risk of one deadly cancer
Health Policy & Health Systems Management
988 Enters Its Fourth Year as Demand Grows and the Mental Health and Substance Use Landscape Shifts
Health Policy & Health Systems Management
